{"name":"Amphastar Pharmaceuticals","slug":"amphastar","ticker":"AMPH","exchange":"NASDAQ","domain":"amphastar.com","description":"Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.","hq":"Rancho Cucamonga, CA, USA","founded":0,"employees":"1976","ceo":"Jack Y. Zhang","sector":"Specialty Injectables / Biosimilars","stockPrice":20.26,"stockChange":-0.32,"stockChangePercent":-1.55,"marketCap":"$931M","metrics":{"revenue":780000000,"revenueGrowth":-1.8,"grossMargin":49.5,"rdSpend":85844000,"netIncome":98094000,"cash":282812000,"dividendYield":0,"peRatio":10,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"Epinephrine Injection patent cliff ($143.8M at risk)","drug":"Epinephrine Injection","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":6,"colorKey":"immunology","drugs":[{"name":"Primatene Mist","genericName":"Primatene Mist","slug":"primatene-mist","indication":"Acute bronchospasm and asthma attacks (over-the-counter emergency relief)","status":"marketed"},{"name":"Arm T1: Primatene Mist HFA","genericName":"Arm T1: Primatene Mist HFA","slug":"arm-t1-primatene-mist-hfa","indication":"Relief of acute asthma symptoms","status":"phase_2"},{"name":"Epinephrine HFA-MDI (E004)","genericName":"Epinephrine HFA-MDI (E004)","slug":"epinephrine-hfa-mdi-e004","indication":"Acute asthma exacerbation","status":"phase_3"},{"name":"albuterol inhalation aerosol","genericName":"albuterol inhalation aerosol","slug":"albuterol-inhalation-aerosol","indication":"Maintenance and relief of bronchospasm in patients with asthma and in patients with COPD","status":"phase_3"},{"name":"albuterol inhalation powder","genericName":"albuterol inhalation powder","slug":"albuterol-inhalation-powder","indication":"Acute bronchospasm relief in asthma","status":"phase_3"},{"name":"epinephrine inhalation aerosol","genericName":"epinephrine inhalation aerosol","slug":"epinephrine-inhalation-aerosol","indication":"Relief of acute bronchospasm in asthma and other obstructive airway diseases","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"Epinephrine inhalation","genericName":"Epinephrine inhalation","slug":"epinephrine-inhalation","indication":"Acute bronchospasm and croup in pediatric patients","status":"marketed"},{"name":"A006 DPI","genericName":"A006 DPI","slug":"a006-dpi","indication":"Other","status":"phase_2"},{"name":"Arm T2: Primatene Mist HFA","genericName":"Arm T2: Primatene Mist HFA","slug":"arm-t2-primatene-mist-hfa","indication":"Other","status":"phase_2"},{"name":"Placebo DPI","genericName":"Placebo DPI","slug":"placebo-dpi","indication":"Clinical trial control / comparator product","status":"marketed"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"A006","genericName":"A006","slug":"a006","indication":"Type 2 diabetes","status":"phase_2"}]}],"pipeline":[{"name":"Epinephrine inhalation","genericName":"Epinephrine inhalation","slug":"epinephrine-inhalation","phase":"marketed","mechanism":"Epinephrine inhalation is a bronchodilator that stimulates alpha and beta-adrenergic receptors to rapidly relieve acute bronchospasm and airway obstruction.","indications":["Acute bronchospasm and croup in pediatric patients","Emergency relief of acute airway obstruction"],"catalyst":""},{"name":"Primatene Mist","genericName":"Primatene Mist","slug":"primatene-mist","phase":"marketed","mechanism":"Epinephrine acts as a beta-2 adrenergic agonist to relax bronchial smooth muscle and relieve acute bronchospasm.","indications":["Acute bronchospasm and asthma attacks (over-the-counter emergency relief)"],"catalyst":""},{"name":"A006","genericName":"A006","slug":"a006","phase":"phase_2","mechanism":"A006 is a small molecule that acts as a selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2).","indications":["Type 2 diabetes"],"catalyst":""},{"name":"A006 DPI","genericName":"A006 DPI","slug":"a006-dpi","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Arm T1: Primatene Mist HFA","genericName":"Arm T1: Primatene Mist HFA","slug":"arm-t1-primatene-mist-hfa","phase":"phase_2","mechanism":"Primatene Mist HFA is a bronchodilator that contains epinephrine, which works by relaxing the muscles in the airways and increasing air flow to the lungs.","indications":["Relief of acute asthma symptoms","Relief of acute bronchospasm in COPD"],"catalyst":""},{"name":"Arm T2: Primatene Mist HFA","genericName":"Arm T2: Primatene Mist HFA","slug":"arm-t2-primatene-mist-hfa","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Epinephrine HFA-MDI (E004)","genericName":"Epinephrine HFA-MDI (E004)","slug":"epinephrine-hfa-mdi-e004","phase":"phase_3","mechanism":"Epinephrine is a sympathomimetic amine that binds to alpha and beta adrenergic receptors to produce rapid bronchodilation, increased heart rate, and vasoconstriction.","indications":["Acute asthma exacerbation","Anaphylaxis"],"catalyst":""},{"name":"Placebo DPI","genericName":"Placebo DPI","slug":"placebo-dpi","phase":"marketed","mechanism":"Placebo DPI is an inert formulation delivered via dry powder inhaler that produces no pharmacological effect.","indications":["Clinical trial control / comparator product"],"catalyst":""},{"name":"albuterol inhalation aerosol","genericName":"albuterol inhalation aerosol","slug":"albuterol-inhalation-aerosol","phase":"phase_3","mechanism":"Albuterol inhalation aerosol is a beta-2 adrenergic receptor agonist that works by relaxing bronchial muscles to improve airflow to the lungs.","indications":["Maintenance and relief of bronchospasm in patients with asthma and in patients with COPD"],"catalyst":""},{"name":"albuterol inhalation powder","genericName":"albuterol inhalation powder","slug":"albuterol-inhalation-powder","phase":"phase_3","mechanism":"Albuterol is a beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle, causing relaxation and bronchodilation.","indications":["Acute bronchospasm relief in asthma","Chronic obstructive pulmonary disease (COPD) maintenance and acute symptom relief"],"catalyst":""},{"name":"epinephrine inhalation aerosol","genericName":"epinephrine inhalation aerosol","slug":"epinephrine-inhalation-aerosol","phase":"phase_3","mechanism":"Epinephrine inhalation aerosol works by stimulating the beta-2 adrenergic receptors in the lungs to cause bronchodilation.","indications":["Relief of acute bronchospasm in asthma and other obstructive airway diseases"],"catalyst":""}],"recentEvents":[{"date":"2023-02-28","type":"earnings","headline":"Amphastar Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results","summary":"Amphastar Pharmaceuticals reported its fourth quarter and full year 2022 financial results, with revenue of $143.8 million and net income of $14.4 million.","drugName":"","sentiment":"neutral"},{"date":"2022-11-14","type":"deal","headline":"Amphastar Pharmaceuticals Announces Agreement with Sandoz to Manufacture and Supply Epinephrine Injection","summary":"Amphastar Pharmaceuticals announced an agreement with Sandoz to manufacture and supply epinephrine injection, a critical care product.","drugName":"","sentiment":"positive"},{"date":"2022-08-09","type":"regulatory","headline":"FDA Approves Amphastar Pharmaceuticals' Epinephrine Injection","summary":"The FDA approved Amphastar Pharmaceuticals' epinephrine injection, a critical care product.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE9yRUxBZ0h2QUh2VWZFQzV3UlZMSlBQQndKTi1DbUV0UlpHdEh5R1lqc1BleEJpRnJfeHp2cXhmWHJMU1UwMDNnQTVpM0phLWM5NzVV?oc=5","date":"2026-04-04","type":"pipeline","source":"Benzinga Japan","summary":"Amphastar Pharma (AMPH) Stock Analysis Report | Ratings, Financials & Performance - Benzinga Japan","headline":"Amphastar Pharma (AMPH) Stock Analysis Report | Ratings, Financials & Performance","sentiment":"neutral"},{"date":"2026-03-16","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-06","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-06","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxOQ1Y1RUxQZUw0eDFUSFFXdG9FU0Y5ME8taDg5QTk0YklnN0lLYkctVFB1dUstZzdfeUpBNjQ3N0FPTzA0UTVtOUpzODBOSHE4VERGRlRPSTFvVFJ3N3BWRXUwdjg0R3VKYTBNcU1maENKRTRoVU9wR01Ca05teDgzbDNnX1o3WndZNG1nNm9OcmZsY29k?oc=5","date":"2026-03-05","type":"earnings","source":"Yahoo Finance","summary":"Generic Pharmaceuticals Stocks Q4 Highlights: Amphastar Pharmaceuticals (NASDAQ:AMPH) - Yahoo Finance","headline":"Generic Pharmaceuticals Stocks Q4 Highlights: Amphastar Pharmaceuticals (NASDAQ:AMPH)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxPbnZRVUJ2RzZHUHp5OW5HMzBMU01iS0l3bnc2ZEJsdll3VDFjLWZPdGNOckpTaUpIYUFzWmFHQi1LX0g1VmlWcE9ybXZ2OEg5NjdYMEpxc0NyOVRwRlFoYTNFME5DcVdvTHpPVHAteGFPb2Z5X3RTOXlZZVFiWXQtbjQxTkU5OWNzYjNiNjJ1MDVtd3BVQlFGdw?oc=5","date":"2026-02-28","type":"regulatory","source":"Seeking Alpha","summary":"Amphastar: Higher Costs, Lower Growth, And A 'Value Trap' Label (NASDAQ:AMPH) - Seeking Alpha","headline":"Amphastar: Higher Costs, Lower Growth, And A 'Value Trap' Label (NASDAQ:AMPH)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxOY1BGbDdHNF9mT1Q3dzJFQmhSVTU0UVQyY1ZzRnlEN1RBTDBlQTNvWG9vQlh1QktMNmw2azdWZVpvVDVsemtwYkpDWFZVOXEycnNPNFEtb0J2REF4bHhsSE16bVp2ckQ5ZGF6N24tSG1Jb1dMa2ZKa0h0UFF1R3NCYXpkdHpIVktIQTQxMkFFRzJfYUI3SklpbVV5SkRBODJkZWZoTWs4Q3RZMm9XdlJVdFRIWkl1c0lvLWZ1QndR?oc=5","date":"2026-02-27","type":"pipeline","source":"TradingView","summary":"Why Amphastar Pharmaceuticals (AMPH) Shares Are Plunging Today - TradingView","headline":"Why Amphastar Pharmaceuticals (AMPH) Shares Are Plunging Today","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxNMTVUMGdmbDhvZ0ZtRUVTZUkybmRENlBfalFkRlVDc2djZ3FmNDQzY0F1Z1d5WlVvU083aEt0VlFWYVdwZ19UVklFcnpxRy04TS1VY1VxaDVfaTl1ZTBPckN5Vkc1T3NwYzdKN1ctU3dUbS1JcjU3LUMwMTY5WlRyTzR3MFVpOEEzLU1XNllwaENEay1VRjcyczRlbXJwaXFlLVV5cDNkVUhiQTJPX3MyVGw4OUVreU9Eck1N?oc=5","date":"2026-02-26","type":"earnings","source":"Finviz","summary":"Amphastar Pharmaceuticals (NASDAQ:AMPH) Misses Q4 CY2025 Revenue Estimates, Stock Drops 11.7% - Finviz","headline":"Amphastar Pharmaceuticals (NASDAQ:AMPH) Misses Q4 CY2025 Revenue Estimates, Stock Drops 11.7%","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxQakZ4T2pYdkpoVl9FendZemN3eVd0S1FYdGp0c05BRWpCMmZQSC1CU1h5dkpUelJCNG9VYmpBa3NrODBvdU92alBlSlF3QWJsZkhRdDJWT3ZtYTRPWkpuS2pmZjFENzVHbW4tTko3VnM0T05ubTMyN0lMNWFCOHNMUFFCaU10MkpFSjdudUs3NEk5S2hxVHdra2Qzdl9CMkhMcktQMA?oc=5","date":"2026-02-25","type":"earnings","source":"Finviz","summary":"Amphastar Pharmaceuticals (AMPH) Reports Earnings Tomorrow: What To Expect - Finviz","headline":"Amphastar Pharmaceuticals (AMPH) Reports Earnings Tomorrow: What To Expect","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxQcmQ0UnU1RmNYN2tGRlRvSFhLcFZCMVJURW84MjBYa2VSNHRKLXFMV2d5My1mMUEtRUFuV0NOdkIwTE5zblJsd2ZKaHBrcTlTaGc5OTMxRjU3QmlsMFBfeUpmd1dmYUhkeFdFdU03UUI4cTNicmRGcEZpQm5oNHlqc01OMmdjOUFqamhYWVpFRExmaXI1T2xzaGlCaG1tY2JFWm5oVXowaU04TER6?oc=5","date":"2026-01-12","type":"deal","source":"Contract Pharma","summary":"Amphastar, Hanxin Enter Exclusive License Agreement for AMP-110 - Contract Pharma","headline":"Amphastar, Hanxin Enter Exclusive License Agreement for AMP-110","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4wFBVV95cUxQSUF5NU5xSVFBXzAwSVM1MmJDekdLQkYtODJpNVF5ODhNQnhnWWthV05FeEc3TFdod0pFVnBPeFRmdzBhblY2aW1XbzVIOVl5Nmx2b1d1a0VDMEwyMVZWa0daZFhpNUhtV2NmclNGT283M3ZtdGgxWXZrNHhHTXJUd1I4QlJ6NFNLMGdGNEVCRTltTW9kRjBKeUVKY3VwTldTQ2N3ZUh0RnNrZzJjNURZTHNLc1A1TnVuRHB1c0l0eVZVdW5wcmN6VmxIbnJhQ3pkVEY5SUtJM0s4dHl0dEMwS2RvNA?oc=5","date":"2026-01-12","type":"deal","source":"ACCESS Newswire","summary":"Amphastar Pharmaceuticals Announces Exclusive License Agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. for Fully Synthetic Corticotropin Compound - ACCESS Newswire","headline":"Amphastar Pharmaceuticals Announces Exclusive License Agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxPU2tOQTJ3ZkRCVldHSUNNRVZua3RrRE5VSExlR29rOFQ2cTRFamtIY2RtUHM4VWFLaDZiQ2VHN29KY0doYTIzRFpJQllxMVVqTmVQZmJ4ZHpsTkwzeGl0REdIRVBmUWtWbDRuQlAxRlRva2hqVHNmZTdZSUQyN2ZzRzhad3JnbmRwWk8zNDNfaw?oc=5","date":"2026-01-12","type":"pipeline","source":"Yahoo Finance","summary":"Why Amphastar Pharmaceuticals (AMPH) Stock Is Trading Up Today - Yahoo Finance","headline":"Why Amphastar Pharmaceuticals (AMPH) Stock Is Trading Up Today","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-09","type":"pipeline","source":"simplywall.st","summary":"Is Amphastar Pharmaceuticals (AMPH) Attractively Priced After Recent Share Price Weakness? - simplywall.st","headline":"Is Amphastar Pharmaceuticals (AMPH) Attractively Priced After Recent Share Price Weakness?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxOZGVYNEJxSllWOVBUeE9SREtvZFVRUi1qU0tDSnhFalJySjhzdWJXUkdrRXlrNDBsdUFLbF9KM2NfOW1YUGUtdnFhWkJXN0xKU05XbVdmRTBiTjMyS0Y2YTByZkZZV1IwNXpPcmNoeWxuX2NvNko5Z0d1NVJPdFBveXI3clBLMTc0N2FLRl9Lc2VKbU9hLVlMemx0M3Ixbk16VVI3VHlia0FDSmEyYzVudWtSSnVtajlWV1VUcmNNSVV2VlNNN281dkhkSTFmbjh0dVI4eldiYmF2dXNXUEd0Vg?oc=5","date":"2025-07-18","type":"pipeline","source":"Pharmaceutical Online","summary":"Amphastar Pharmaceuticals Announces Multi-Year Expansion Of US Manufacturing Operations In California - Pharmaceutical Online","headline":"Amphastar Pharmaceuticals Announces Multi-Year Expansion Of US Manufacturing Operations In California","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE1VNHVrcUtkeU9sV0RNOVU2VVZibXhqUy14cUo1QVJPVXpEXzc3NGlvNWF4NlN4ZnoyQ0h4YXAtY1pYZjFNS0tTM0hZQ3BfZngweUlv?oc=5","date":"2025-04-24","type":"pipeline","source":"Stock Titan","summary":"AMPH Stock Price, News & Analysis - Stock Titan","headline":"AMPH Stock Price, News & Analysis","sentiment":"neutral"}],"patents":[{"drugName":"Epinephrine Injection","drugSlug":"epinephrine","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":143800000}],"drugCount":11,"phaseCounts":{"marketed":3,"phase_2":4,"phase_3":4},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Sandoz","Mallinckrodt","Hikma Pharmaceuticals"],"therapeuticFocus":["Critical Care","Hospital Products"],"financials":{"source":"sec_edgar","revenue":719887000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":719887000,"period":"2025-12-31"},{"value":731967000,"period":"2024-12-31"},{"value":731967000,"period":"2024-12-31"},{"value":644395000,"period":"2023-12-31"},{"value":644395000,"period":"2023-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":85844000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":98094000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":1629299000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":20.26,"previousClose":20.58,"fiftyTwoWeekHigh":31.26,"fiftyTwoWeekLow":17.03,"fiftyTwoWeekRange":"17.03 - 31.26","fiftyDayAverage":23.47,"twoHundredDayAverage":25.23,"beta":0.91,"enterpriseValue":1306908160,"forwardPE":5.8,"priceToBook":1.17,"priceToSales":1.29,"enterpriseToRevenue":1.81,"enterpriseToEbitda":5.93,"pegRatio":0,"ebitda":220198000,"ebitdaMargin":30.6,"freeCashflow":81365248,"operatingCashflow":156115008,"totalDebt":656001984,"debtToEquity":83.2,"currentRatio":4.02,"returnOnAssets":6.4,"returnOnEquity":12.9,"analystRating":"","recommendationKey":"none","numberOfAnalysts":7,"targetMeanPrice":29,"targetHighPrice":30,"targetLowPrice":25,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":25.2,"institutionHeldPercent":76.6,"sharesOutstanding":45370171,"floatShares":34115646,"sharesShort":3738333,"shortRatio":5.66,"shortPercentOfFloat":8.2,"epsTrailing":2.03,"epsForward":3.49,"revenuePerShare":15.4,"bookValue":17.28,"officers":[{"age":75,"name":"Dr. Ziping  Luo Ph.D.","title":"Chairman of the Board, Chief Scientist & COO"},{"age":78,"name":"Dr. Yongfeng  Zhang Ph.D.","title":"Co-Founder, President, CEO, Chief Scientific Officer & Director"},{"age":57,"name":"Mr. William J. Peters M.B.A.","title":"CFO, Executive VP of Finance, Treasurer & Director"},{"age":50,"name":"Mr. Jacob  Liawatidewi M.B.A.","title":"Executive VP of Sales, Marketing & Corporate Administration Center, Corporate Secretary and Director"},{"age":66,"name":"Mr. Rong  Zhou M.S.","title":"Senior EVP of Production & EVP of Scientific Affairs"},{"age":null,"name":"Mr. Dan  Dischner M.B.A.","title":"Senior Vice President of Human Resources & Corporate Communication"},{"age":null,"name":"Tony  Marrs M.B.A., M.P.H., M.S.","title":"Executive VP of Regulatory Affairs & Clinical Operations"}],"industry":"Drug Manufacturers - Specialty & Generic","irWebsite":"","website":"https://www.amphastar.com","phone":"909 980 9484"}}